skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

What major drug catalysts and events can you expect to see this quarter?

Download your free Biomedtracker/Meddevicetracker Q4 2019 Outlook Report, a data driven assessment of the likelihood of approval for an array of drugs. 

Get a view of what’s to come with an extract from the full report, containing:

Data for 33 drugs, diagnostics, and devices
Likelihood of Phase/PDUFA review success for each
Q4 expected large impact catalysts
A look back at the outcomes from the Q3 Outlook report
Overall Likelihood of Approval (LOA) based on phase, drug class, and disease group
Benchmarking data from Pharmapremia

JN2646_Cov_Ima_Q4_2019_Outlook_Report_Extract

Read also

  • Biomedtracker: see the drug development process through anal...

    39th Annual J.P. Morgan Healthcare Conference 2021

    Keep up with events as they unfold at the 39th Annual J.P. Morgan Annual Healthcare Conference on January 11-14, 2021. Pharma Intelligence and Insights journalists will bring you real time reporting, highlighting important events and key takeaways from every day of the largest and most informative healthcare investment symposium in the industry.

  • Medtech Insight: global medical technology news & analysis, ...

    Meddevicetracker & Medtech Insight Spinal Device Markets

    Discover what’s on the horizon for spinal devices and technology with news, analysis, and data from Medtech Insight and Meddevicetracker. Keep up with the latest developments from the annual NASS meeting and explore extracts from two data-packed recent reports: Spinal Fusion Implanted Instrumentation and Spinal Motion Preservation Devices Market.

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    Gene therapy manufacturers

    Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: